600276 恒瑞医药
交易中 04-16 14:51:59
资讯
新帖
简况
恒瑞医药(01276)：HRS-7156片获得药物临床试验批准通知书
智通财经 · 04-15 18:42
恒瑞医药(01276)：HRS-7156片获得药物临床试验批准通知书
恒瑞医药(01276)4月14日斥资245.13万元回购4.4万股A股
智通财经 · 04-14 17:09
恒瑞医药(01276)4月14日斥资245.13万元回购4.4万股A股
口服减肥药大战打响
国际金融报 · 04-13 17:24
口服减肥药大战打响
AH溢价走低的成因与展望
蓝鲸财经 · 04-11
AH溢价走低的成因与展望
恒瑞医药(01276)：HRS-5765片获得药物临床试验批准通知书
智通财经 · 04-10
恒瑞医药(01276)：HRS-5765片获得药物临床试验批准通知书
摩根士丹利增持恒瑞医药H股 持股比例从1.17%跃升至9.85%
美股速递 · 04-09
摩根士丹利增持恒瑞医药H股 持股比例从1.17%跃升至9.85%
恒瑞医药(01276)4月7日斥资362.15万元回购6.48万股A股
智通财经 · 04-08
恒瑞医药(01276)4月7日斥资362.15万元回购6.48万股A股
恒瑞医药：公司有10款产品于2025年12月首次纳入国家医保目录
证券日报 · 04-03
恒瑞医药：公司有10款产品于2025年12月首次纳入国家医保目录
恒瑞医药：公司目前产品暂不涉及脑机接口相关领域
每日经济新闻 · 04-03
恒瑞医药：公司目前产品暂不涉及脑机接口相关领域
恒瑞医药累计回购1195万股 金额7.66亿元
财中社 · 04-02
恒瑞医药累计回购1195万股 金额7.66亿元
大摩：给予恒瑞医药(01276)“增持”评级 目标价92港元
智通财经 · 04-01
大摩：给予恒瑞医药(01276)“增持”评级 目标价92港元
恒瑞医药：创新药收入突破163亿，对外许可常态化打开增长新空间
证券市场周刊 · 03-31
恒瑞医药：创新药收入突破163亿，对外许可常态化打开增长新空间
恒瑞医药披露Myosin抑制剂HRS-1893治疗梗阻性肥厚型心肌病II期研究积极结果
每日经济新闻 · 03-31
恒瑞医药披露Myosin抑制剂HRS-1893治疗梗阻性肥厚型心肌病II期研究积极结果
恒瑞医药与Braveheart Bio公布HRS/BHB-1893治疗梗阻性肥厚型心肌病二期试验积极结果
美股速递 · 03-30
恒瑞医药与Braveheart Bio公布HRS/BHB-1893治疗梗阻性肥厚型心肌病二期试验积极结果
营收316亿、净利增超21% 恒瑞医药2025年财报释放强劲动能
中金财经 · 03-30
营收316亿、净利增超21% 恒瑞医药2025年财报释放强劲动能
【券商聚焦】交银国际维持恒瑞医药(01276)中性评级 指新品放量+国际化共驱高增长
金吾财讯 · 03-30
【券商聚焦】交银国际维持恒瑞医药(01276)中性评级 指新品放量+国际化共驱高增长
港股异动 | 先声药业(02096)午前涨近8% 恒瑞医药前董事长周云曙正式出任先声药业CEO
智通财经 · 03-27
港股异动 | 先声药业(02096)午前涨近8% 恒瑞医药前董事长周云曙正式出任先声药业CEO
信达生物2025年首次扭亏为盈；周云曙出任先声药业CEO | 医药早参
每日经济新闻 · 03-27
信达生物2025年首次扭亏为盈；周云曙出任先声药业CEO | 医药早参
恒瑞医药创新药收入占比近六成 BD重构国际化价值锚点
21世纪经济报道 · 03-27
恒瑞医药创新药收入占比近六成 BD重构国际化价值锚点
恒瑞医药(600276.SH)：HRS9531注射液获得药物临床试验批准通知书
智通财经 · 03-26
恒瑞医药(600276.SH)：HRS9531注射液获得药物临床试验批准通知书
加载更多
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":57.46,"timestamp":1776322319000,"preClose":57.73,"halted":0,"volume":55432723,"delay":0,"changeRate":-0.0047,"floatShares":6379000000,"shares":6637000000,"eps":1.3689,"marketStatus":"交易中","change":-0.27,"latestTime":"04-16 14:51:59","open":57.98,"high":58,"low":57.02,"amount":3183000000,"amplitude":0.017,"askPrice":57.47,"askSize":517,"bidPrice":57.46,"bidSize":83,"shortable":0,"etf":0,"ttmEps":1.3689,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1776322800000},"marketStatusCode":2,"adr":0,"adjPreClose":57.73,"symbolType":"stock","openAndCloseTimeList":[[1776303000000,1776310200000],[1776315600000,1776322800000]],"highLimit":63.5,"lowLimit":51.96,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":6.25,"roa":"--","peRate":41.975309,"roe":"14.26%","epsLYR":1.19,"committee":0.110628,"marketValue":381374000000,"turnoverRate":0.0087,"status":1,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":68.25,"timestamp":1776322320834,"preClose":68.3,"halted":0,"volume":2519919,"delay":0,"premium":"+3.37"},"floatMarketCap":366537000000},"requestUrl":"/m/hq/s/600276","defaultTab":"news","newsList":[{"id":"2627856502","title":"恒瑞医药(01276)：HRS-7156片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2627856502","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627856502?lang=zh_cn&edition=full","pubTime":"2026-04-15 18:42","pubTimestamp":1776249773,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，近日，江苏恒瑞医药股份有限公司(以下简称“公司”)子公司山东盛迪医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于 HRS-7156 片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-7156 片是公司自主研发的1类新药。临床前数据显示，HRS-7156可显着改善心脏功能和病变。经查询，目前国内外暂无同类药物获批上市。截至目前， HRS-7156 片相关项目累计研发投入约为3,760万元(未经审计)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828631.EUR","BK0028","600276","LU2328871848.SGD","LU1781817850.SGD","LU2289578879.USD","BK0188","BK0183","LU0359202008.SGD","LU1997244956.HKD","LU1580142542.USD","BK0239","BK0012","LU1255011170.USD","LU2097828805.USD","LU1146622755.USD","LU1820825898.SGD","LU2488822045.USD","LU1655091616.SGD","LU2097828557.USD","LU2097828714.EUR","LU1064131003.USD","BK0060","LU1997245177.USD","BK0196","LU0359201885.HKD","01276","LU2580892789.USD","LU2580892862.HKD","LU2495084118.USD","BK1191","LU2543165471.USD","LU0359201612.USD","LU1023057109.AUD","LU2148510915.USD","LU1969619763.USD","LU2097828474.EUR","LU0405327494.USD","LU0405327148.USD","LU1997245094.SGD","LU1064130708.USD","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627701419","title":"恒瑞医药(01276)4月14日斥资245.13万元回购4.4万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627701419","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627701419?lang=zh_cn&edition=full","pubTime":"2026-04-14 17:09","pubTimestamp":1776157754,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年4月14日斥资人民币245.13万元回购4.4万股A股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428312.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828557.USD","01276","LU2543165471.USD","LU1580142542.USD","BK0188","LU1820825898.SGD","LU1023057109.AUD","LU2328871848.SGD","LU1146622755.USD","LU0359201885.HKD","LU1328615791.USD","LU1064131003.USD","LU0359202008.SGD","LU0405327148.USD","BK0060","BK0183","LU0405327494.USD","LU2148510915.USD","LU2289578879.USD","LU2580892862.HKD","BK0196","LU2495084118.USD","LU1997245094.SGD","LU2097828631.EUR","LU2488822045.USD","159982","LU2580892789.USD","LU1997245177.USD","LU1255011170.USD","LU1655091616.SGD","LU1997244956.HKD","LU2097828714.EUR","LU1781817850.SGD","BK0012","BK1191","LU1064130708.USD","BK0239","LU2097828805.USD","BK0028","LU0359201612.USD","600276","399300","LU1969619763.USD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627439545","title":"口服减肥药大战打响","url":"https://stock-news.laohu8.com/highlight/detail?id=2627439545","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627439545?lang=zh_cn&edition=full","pubTime":"2026-04-13 17:24","pubTimestamp":1776072286,"startTime":"0","endTime":"0","summary":"张力制表2026年，减肥药赛道早已告别诺和诺德一家独大的旧格局。随着司美格鲁肽核心化合物专利到期，国内市场迎来全新竞争态势：信达生物玛仕度肽注射液III期临床试验成功达成主要终点，来凯医药、先为达生物等本土企业则加速冲刺港股IPO，试图在资本与市场的双重赛道抢占先机。进入4月份，口服剂型的商业化落地，成为全球减肥药赛道的新焦点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604133702961635.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604133702961635.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BKVL7J92.USD","BK4588","600276","BK4007","BK4585","LLY","LU1093756325.SGD","NVO","IPOS","NVOH","600745","LU0154236417.USD","BK4599","01276","NVOX","IE00BZ1G4Q59.USD","BK4532","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626128031","title":"AH溢价走低的成因与展望","url":"https://stock-news.laohu8.com/highlight/detail?id=2626128031","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626128031?lang=zh_cn&edition=full","pubTime":"2026-04-11 17:09","pubTimestamp":1775898556,"startTime":"0","endTime":"0","summary":"文｜财华社恒生沪深港通AH股溢价指数持续走低，从2024年2月接近158点的高位回落，至2026年初为123.48点，现报118.94点，见下图，显示AH股估值差距正逐步收敛。这类高溢价的形成，核心与行业属性及A股资金偏好密切相关。但需注意，当前赴港上市的A股公司以优质龙头为主，其H股定价更受国际资金认可，短期供给冲击有限，难以改变溢价率收敛的整体趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1775802053606341910","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU0509642566.USD","002703","LU1008478684.HKD","LU1861219969.SGD","000338","LU1820825898.SGD","LU1880383366.USD","LU1366334578.USD","IE0031814852.USD","BK1202","LU2125910500.SGD","LU0417516738.SGD","LU0261950470.USD","LU0417516902.SGD","LU0163747925.USD","LU0359202008.SGD","IE0003851619.USD","LU0821914370.USD","LU1251922891.USD","LU1960683339.HKD","600276","LU1152091168.USD","LU0828237940.HKD","BK1562","LU0823414551.USD","LU0370786039.SGD","LU1303224171.USD","LU0862451753.SGD","LU1328277881.USD","LU0320764599.SGD","IE00BZ08YT58.USD","LU0192582467.USD","LU0651946864.USD","HK0000181112.HKD","IE0008368742.USD","LU2097828557.USD","LU2360107325.USD","LU0431992006.USD","LU0106252389.USD","BK0010","LU1244550494.USD","BK0188","LU0823437842.USD","LU1580142542.USD","LU0259732245.USD","BK0183","LU0502904849.HKD","LU0737861699.HKD","LU0918141887.USD","02338","LU0708995583.HKD","HK0000181138.USD","BK0012","LU0128522744.USD","LU2039709279.SGD","LU0143863198.USD","LU1720050803.USD","LU0128522157.USD","LU0054450605.USD","LU0456846285.SGD","LU0540923850.HKD","001236","LU2506951792.HKD","LU0724618433.USD","LU0880133367.SGD","LU0708995153.HKD","LU1997244956.HKD","LU1808992512.USD","LU1961090484.USD","LU0315179316.USD","IE00BVYPNP33.GBP","LU1046422090.SGD","LU0029874905.USD","SG9999014674.SGD","LU1242518931.SGD","HK0000352382.USD","LU1880383440.USD","LU2399975544.HKD","LU0359201885.HKD","IE0008369823.USD","LU2506952337.HKD","LU0348814723.USD","LU0634319403.HKD","SG9999001903.USD","LU1794554557.SGD","LU0181495838.USD","LU0359201612.USD","605198","LU0543330566.HKD","SG9999000459.SGD","LU1831875114.USD","LU0650527681.SGD","LU1868837565.USD","LU2097828631.EUR","IE00BYV24P56.USD","LU0594300179.USD","LU0164865239.USD","01276","LU2298322129.HKD","03678","IE0003795394.USD","IE00BD6J9T35.USD","LU2153592121.USD","LU0072913022.USD","LU2148510915.USD","IE00BZ08YR35.GBP","LU0165289439.USD","LU0244354667.USD","LU2348773727.SGD","IE00BPRC5H50.USD","IE00BGHQDM52.EUR","LU0117841782.USD","LU1051768304.USD","LU0531970944.HKD","LU2580892862.HKD","LU2275660780.HKD","LU2506952410.USD","LU0048575426.USD","603986","LU0469268626.HKD","SG9999000327.SGD","BK0214","HK0000352291.HKD","LU1934453819.USD","LU0048580855.USD","02218","LU1115378108.SGD","LU1721428347.USD","LU2477742899.HKD","LU0320764755.SGD","BK1507","LU0327786744.USD","LU1997245177.USD","LU1978683503.SGD","LU0348825331.USD","LU0149534421.HKD","LU0132412106.USD","300750","LU0348788117.USD","LU0384037296.USD","LU2506952253.HKD","LU0302445910.USD","BK4588","LU1255011170.USD","LU2238339852.HKD","BK1560","BK1144","BK0102","LU0449515922.USD","LU0164872284.USD","LU0823426480.USD","LU0188438112.USD","600036","LU1769817179.HKD","IE00B8L5B284.USD","LU0505663152.USD","BK0070","CIHKY","LU0589944569.HKD","LU2495084118.USD","600871","LU0067412154.USD","LU0823426308.USD","LU0531971595.HKD","IE00B8HQ1Z84.USD","01033","BK1191","LU2476274308.USD","LU0871576103.HKD","LU1813983027.USD","LU0052750758.USD","06809","LU1719994722.HKD","LU0043850808.USD","LU1282649141.HKD","LU0488056044.USD","LU0501845795.SGD","LU0593848301.USD","LU1224709979.USD","03986","BK1610","BK1231","LU1675838814.USD","LU0307460666.USD","LU0106959298.USD","LU0979878070.USD","BK1521","01349","LU0868486357.SGD","LU1939255532.USD","LU0214875030.USD","LU1105468828.SGD","LU0173614495.USD","03968","LU2424517915.HKD","LU0890818403.SGD","LU2294711713.HKD","BK0028","LU2298064838.USD","LU1997245094.SGD","BK0224","IE00BVYPNQ40.USD","LU0312595415.SGD","LU1039395188.USD","BK1522","LU0449509016.USD","SG9999004220.SGD","IE00B5MMRT66.SGD","IE00B29SXG58.USD","LU1064130708.USD","LU0405327494.USD","SG9999002828.SGD","SG9999001689.USD","LU0791591158.USD","LU1655091616.SGD","LU0039217434.USD","LU0210526637.USD","LU1282648689.USD","LU0516422952.EUR","LU2226246903.HKD","LU0072462343.USD","LU2213484517.USD","01057","LU0107464264.USD","LU1282649810.SGD","LU2097828714.EUR","LU0140636845.USD","LU1769817096.USD","BK0187","LU0228659784.USD","LU1366334651.USD","LU1102505762.USD","LU2543165471.USD","LU0348805143.USD","LU1226287529.USD","688008","LU1102505929.USD","BK0278","LU1048588211.SGD","LU0516422440.USD","688505","LU1969619763.USD","LU0320764243.SGD","LU2294711473.HKD","LU0231483743.USD","LU2097828805.USD","LU0456842615.SGD","LU1152091754.HKD","00553","BK0125","BK1576","LU0328353924.USD","03750","LU2348774022.SGD","LU0106259558.USD","LU0456827905.SGD","LU0348735423.USD","02359","LU0051755006.USD","SG9999001846.SGD","BK4585","LU1861214812.USD","LU0143863784.USD","LU2778985437.USD","BK1116","LU0516423091.SGD","LU0348816934.USD","LU0455707207.USD","SG9999002463.SGD","LU0228367735.SGD","BK1171","LU1979443071.USD","IE00BZ08YS42.EUR","LU2249611893.SGD","LU0828238088.HKD","LU1051769294.HKD","LU1244550577.SGD","LU0607220059.USD","LU1688375341.USD","LU0594300419.USD","LU2289578879.USD","LU0918141705.HKD","LU0572944931.SGD","LU2357125470.USD","SG9999006597.SGD","BK1237","BK1149","LU0605514214.HKD","SGXZ81163826.USD","LU0611395673.USD","LU1781817850.SGD","LU0651947912.USD","LU2153591404.USD","LU1244550221.USD","IE00B543WZ88.USD","LU0011963245.USD","IE00BF5LJ272.USD","LU2580892789.USD","SGXZ49509284.SGD","LU1064131003.USD","IE00B3M56506.USD","IE0032431581.USD","SG9999003461.SGD","LU0561508036.HKD","LU1282649067.USD","LU2328871848.SGD","LU2152927971.USD","LU1211504680.USD","BK1147","LU0516423174.USD","LU1242518857.USD","LU0049853897.USD","LU0828237510.HKD","LU0314109678.HKD","LU0326948709.USD","LU3063872942.SGD","LU2449936058.SGD","LU0543330483.HKD","BK1564","BK1141","BK1163","LU0287142896.SGD","LU1807302812.USD","LU0588546209.SGD","LU1023057109.AUD","LU0029875118.USD","IE0034224299.USD","LU0640798160.USD","LU0797268264.HKD","IE00B031HY20.USD","LU2476274720.SGD","LU0326950275.SGD","603259","LU0251143458.SGD","IE00BZ199S13.USD","LU0791590937.USD","LU1146622755.USD","IE00B031J352.USD","BK0015","03143","BK1583","LU1770034418.SGD","LU0254981946.USD","600775","LU0124384867.USD","LU0823414478.USD","LU0672654166.SGD","IE00BMCWC346.EUR","LU0648948544.HKD","EVS.SI","LU0405327148.USD","LU0463099449.HKD","LU2097828474.EUR","LU0516422366.SGD","LU0047713382.USD","LU0269904917.USD","LU0229945570.USD","LU1188198961.HKD","LU2045819591.USD","BK0132","LU0048388663.USD","LU1515016050.SGD","LU1993786604.SGD","LU1868838027.USD","LU2242644610.SGD","LU0348827113.USD","LU1048596156.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626193994","title":"恒瑞医药(01276)：HRS-5765片获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2626193994","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626193994?lang=zh_cn&edition=full","pubTime":"2026-04-10 17:07","pubTimestamp":1775812071,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，近日，江苏恒瑞医药股份有限公司(以下简称“公司”)子公司成都盛迪医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于 HRS-5765 片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-5765 片是公司自主研发的 1 类新药，临床前数据显示，HRS-5765 可显著改善心脏功能和病变。经查询，目前国内外暂无同类药物获批上市。截至目前， HRS-5765 片相关项目累计研发投入约 1,380 万元(未经审计)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997245094.SGD","LU1655091616.SGD","LU1820825898.SGD","LU2289578879.USD","LU2097828631.EUR","LU2488822045.USD","LU1997244956.HKD","LU0359202008.SGD","LU2148510915.USD","LU2097828474.EUR","LU2543165471.USD","LU2097828805.USD","BK0239","LU1781817850.SGD","LU2328871848.SGD","LU1064130708.USD","BK0196","LU0359201612.USD","BK0183","LU2580892862.HKD","LU1146622755.USD","LU2580892789.USD","BK0188","BK0028","BK0060","LU2097828714.EUR","LU1064131003.USD","LU1023057109.AUD","LU0405327494.USD","LU2097828557.USD","BK1191","LU1328615791.USD","LU1580142542.USD","BK0012","LU1969619763.USD","LU2495084118.USD","01276","LU0359201885.HKD","LU1255011170.USD","LU1997245177.USD","600276","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183475270","title":"摩根士丹利增持恒瑞医药H股 持股比例从1.17%跃升至9.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183475270","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183475270?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:33","pubTimestamp":1775727201,"startTime":"0","endTime":"0","summary":"根据香港交易所最新披露的数据显示，国际投行摩根士丹利对江苏恒瑞医药H股的持仓出现显著变动。截至4月1日，其持有的多头头寸比例由原先的1.17%大幅提升至9.85%，增幅超过8个百分点。\n这一持股变动反映出摩根士丹利对恒瑞医药未来发展的强烈信心。作为国内创新药龙头企业，恒瑞医药近年来持续加大研发投入，其产品管线覆盖抗肿瘤、麻醉、造影剂等多个重点领域。\n此次持股比例的大幅提升，可能与国际资本看好中国医药行业长期发展潜力相关。在带量采购政策常态化背景下，具备核心创新能力的药企有望获得更多市场关注。机构投资者持仓变动往往被视为行业风向标，此次增持行为或引发市场对创新药板块的重新评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201885.HKD","LU0359202008.SGD","600276","LU1146622755.USD","LU2097828557.USD","BK1191","LU2097828805.USD","LU2289578879.USD","LU1580142542.USD","LU1328615791.USD","LU1255011170.USD","BK0196","BK0028","LU1064130708.USD","LU1023057109.AUD","BK0183","LU1969619763.USD","LU1820825898.SGD","LU0405327148.USD","LU2148510915.USD","LU1781817850.SGD","BK0012","LU2580892789.USD","LU2097828714.EUR","LU2328871848.SGD","LU2580892862.HKD","LU1997244956.HKD","LU2097828474.EUR","01276","LU2495084118.USD","LU0405327494.USD","BK0060","LU2097828631.EUR","LU2543165471.USD","LU1997245094.SGD","BK0188","LU0359201612.USD","LU1655091616.SGD","LU1997245177.USD","LU1064131003.USD","BK0239","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625796100","title":"恒瑞医药(01276)4月7日斥资362.15万元回购6.48万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625796100","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625796100?lang=zh_cn&edition=full","pubTime":"2026-04-08 06:30","pubTimestamp":1775601039,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年4月7日斥资362.15万元回购6.48万股A股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","LU1146622755.USD","LU2328871848.SGD","LU1064130708.USD","LU2580892789.USD","BK0012","LU2289578879.USD","LU1997245177.USD","LU2097828474.EUR","LU0405327494.USD","LU2097828805.USD","159982","LU1328615791.USD","LU1064131003.USD","LU0405327148.USD","LU1781817850.SGD","BK0028","LU1997244956.HKD","BK0183","BK0060","LU0359201885.HKD","LU2488822045.USD","LU1655091616.SGD","LU1023057109.AUD","LU1580142542.USD","LU1820825898.SGD","LU2495084118.USD","BK0239","LU2580892862.HKD","LU0359202008.SGD","BK1191","LU1255011170.USD","LU1969619763.USD","399300","01276","600276","BK0188","LU2543165471.USD","LU0359201612.USD","LU2097828631.EUR","LU2148510915.USD","LU1997245094.SGD","LU2097828714.EUR","LU2097828557.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624792668","title":"恒瑞医药：公司有10款产品于2025年12月首次纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2624792668","media":"证券日报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624792668?lang=zh_cn&edition=full","pubTime":"2026-04-03 21:57","pubTimestamp":1775224620,"startTime":"0","endTime":"0","summary":"证券日报网讯4月3日，恒瑞医药在互动平台回答投资者提问时表示，公司有10款产品于2025年12月首次纳入国家医保目录，将促进公司产品惠及更多患者；公司自主研发的1类创新药瑞拉芙普α注射液于2026年1月获批上市，目前公司已在国内获批上市24款1类创新药及5款2类新药。公司预计2026-2028年获批上市创新产品或适应症约53项，具体详见公司2025年年报附表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695264243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2543165471.USD","BK0196","BK0239","LU1781817850.SGD","LU2097828805.USD","LU1328615791.USD","BK0012","LU2488822045.USD","LU2580892862.HKD","LU2097828557.USD","LU1023057109.AUD","LU0359202008.SGD","LU2495084118.USD","LU2580892789.USD","LU2097828631.EUR","LU1997245094.SGD","BK0060","LU1064131003.USD","LU1655091616.SGD","LU2097828714.EUR","LU1146622755.USD","LU0359201612.USD","LU2289578879.USD","01276","BK0028","BK0188","LU2148510915.USD","LU0405327494.USD","LU1969619763.USD","BK0183","LU0359201885.HKD","LU1820825898.SGD","LU1064130708.USD","LU1255011170.USD","LU1580142542.USD","LU2097828474.EUR","LU1997244956.HKD","LU2328871848.SGD","LU0405327148.USD","LU1997245177.USD","600276","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624659702","title":"恒瑞医药：公司目前产品暂不涉及脑机接口相关领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2624659702","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624659702?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:48","pubTimestamp":1775209711,"startTime":"0","endTime":"0","summary":"【恒瑞医药：公司目前产品暂不涉及脑机接口相关领域】恒瑞医药（600276.SH）4月3日在投资者互动平台表示，公司目前产品暂不涉及相关领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604033695050841.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604033695050841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0405327148.USD","LU2495084118.USD","BK0196","LU1255011170.USD","LU1064130708.USD","LU1580142542.USD","LU2488822045.USD","LU1781817850.SGD","LU2289578879.USD","LU1655091616.SGD","LU1023057109.AUD","LU2097828631.EUR","LU1328615791.USD","LU0359201612.USD","BK1191","BK0188","BK0028","LU0359202008.SGD","LU1997245177.USD","LU1064131003.USD","LU0359201885.HKD","LU1997245094.SGD","LU2328871848.SGD","BK0012","BK0060","LU2543165471.USD","BK0239","01276","LU2097828805.USD","LU1146622755.USD","LU1969619763.USD","LU2580892862.HKD","LU2097828474.EUR","LU2148510915.USD","LU1820825898.SGD","LU2097828714.EUR","LU2097828557.USD","BK0183","LU2580892789.USD","LU1997244956.HKD","LU0405327494.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624746945","title":"恒瑞医药累计回购1195万股 金额7.66亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624746945","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624746945?lang=zh_cn&edition=full","pubTime":"2026-04-02 16:43","pubTimestamp":1775119380,"startTime":"0","endTime":"0","summary":"4月2日，恒瑞医药（600276/01276）发布公告，截至2026年3月31日，公司累计回购1195万股，占总股本的0.18%，回购金额为7.66亿元，回购价格区间为53.52元/股至70元/股。2025年，恒瑞医药实现收入316.29亿元，归母净利润77.11亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023693461666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1655091616.SGD","LU0405327494.USD","LU1580142542.USD","LU2097828474.EUR","LU1146622755.USD","LU2289578879.USD","LU2580892862.HKD","LU0405327148.USD","BK0239","BK1191","LU2097828557.USD","LU1781817850.SGD","BK0012","BK0196","LU2543165471.USD","600276","LU2097828805.USD","BK0060","LU1064131003.USD","LU0359202008.SGD","LU2488822045.USD","LU1255011170.USD","BK0188","LU2097828631.EUR","LU0359201612.USD","BK0183","LU1997245094.SGD","LU2328871848.SGD","LU2097828714.EUR","LU2580892789.USD","LU1023057109.AUD","BK0028","LU1820825898.SGD","LU1064130708.USD","LU2495084118.USD","01276","LU1328615791.USD","LU1997245177.USD","LU2148510915.USD","LU0359201885.HKD","LU1997244956.HKD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624564226","title":"大摩：给予恒瑞医药(01276)“增持”评级 目标价92港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624564226","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624564226?lang=zh_cn&edition=full","pubTime":"2026-04-01 13:50","pubTimestamp":1775022602,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研报称，予恒瑞医药目标价92港元，评级“增持”，指恒瑞医药正迈入全球化新时代，凭借领先的研发实力和销售能力，预期2026至2028年创新药销售年增长率分别达31.5%、29.9%及28.7%，列首选股之一。大摩认为，恒瑞医药有望持续巩固其在中国生物医药行业的龙头地位，并指出市场尚未充分反映其全球化授权出海带来的增长潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423835.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","600276","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623330120","title":"恒瑞医药：创新药收入突破163亿，对外许可常态化打开增长新空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2623330120","media":"证券市场周刊","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623330120?lang=zh_cn&edition=full","pubTime":"2026-03-31 16:15","pubTimestamp":1774944914,"startTime":"0","endTime":"0","summary":"近日，恒瑞医药（600276.SH）发布2025年年度报告。报告显示，公司全年实现营业收入316.29亿元，同比增长13.02%；实现归母净利润77.11亿元，同比增长21.69%；现金流达112.35亿元，同比增长51.36%。报告期间在创新药成果加速转化与对外许可收入常态化入账的双重驱动下，公司业绩实现稳健增长，经营质量持续优化，展现出从研发投入到商业变现的良性循环能力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690397891.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","LU1146622755.USD","LU1997245177.USD","LU0359202008.SGD","BK1574","LU1064130708.USD","LU2289578879.USD","BK1161","LU0405327148.USD","LU2495084118.USD","LU1328615791.USD","BK0012","BK0196","BK0239","06978","01276","LU2148510915.USD","LU1580142542.USD","LU1781817850.SGD","BK0060","LU2097828474.EUR","LU1969619763.USD","LU1997245094.SGD","LU2097828557.USD","LU1820825898.SGD","BK0028","LU1255011170.USD","LU2097828631.EUR","LU0359201612.USD","LU0359201885.HKD","159992","BK0188","LU2580892862.HKD","LU1997244956.HKD","LU2328871848.SGD","LU2580892789.USD","LU2488822045.USD","BK1191","LU2097828805.USD","LU1023057109.AUD","LU2543165471.USD","600276","LU2097828714.EUR","LU1655091616.SGD","LU1064131003.USD","LU0405327494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623637146","title":"恒瑞医药披露Myosin抑制剂HRS-1893治疗梗阻性肥厚型心肌病II期研究积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2623637146","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623637146?lang=zh_cn&edition=full","pubTime":"2026-03-31 10:24","pubTimestamp":1774923855,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月31日，恒瑞医药公众号消息显示，恒瑞医药与BraveheartBio在第75届美国心脏病学会年度科学会议上共同公布了新一代在研心肌肌球蛋白（Myosin）小分子抑制剂HRS-1893（也称BHB-1893）用于梗阻性肥厚型心肌病(oHCM)受试者的II期临床试验数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603313690111336.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690111336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359201612.USD","LU1328615791.USD","LU1064131003.USD","LU1146622755.USD","LU1655091616.SGD","LU0405327494.USD","LU1997245177.USD","BK1191","BK0028","LU2097828714.EUR","LU2289578879.USD","BK0183","BK0188","LU2097828631.EUR","LU2328871848.SGD","BK0012","LU1064130708.USD","01276","LU1781817850.SGD","LU2580892789.USD","BK0239","LU0405327148.USD","600276","LU2488822045.USD","LU0359201885.HKD","LU2543165471.USD","LU2495084118.USD","LU1580142542.USD","LU1820825898.SGD","LU2148510915.USD","BK0060","LU1023057109.AUD","BK0196","LU1255011170.USD","LU2580892862.HKD","LU0359202008.SGD","LU2097828805.USD","LU2097828557.USD","LU1997245094.SGD","LU1969619763.USD","LU1997244956.HKD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110597226","title":"恒瑞医药与Braveheart Bio公布HRS/BHB-1893治疗梗阻性肥厚型心肌病二期试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1110597226","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110597226?lang=zh_cn&edition=full","pubTime":"2026-03-30 21:38","pubTimestamp":1774877897,"startTime":"0","endTime":"0","summary":"恒瑞医药与Braveheart Bio共同宣布，其合作研发的创新药物HRS/BHB-1893在梗阻性肥厚型心肌病的二期临床试验中取得突破性进展。试验数据显示，该药物在主要疗效终点上表现出显著优势，患者的心功能指标与生活质量均获明显改善。此次成果为后续三期临床研究奠定了坚实基础，也为全球梗阻性肥厚型心肌病患者提供了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0012","LU1997244956.HKD","LU0405327494.USD","LU1023057109.AUD","LU1255011170.USD","LU2148510915.USD","BK0028","LU2097828557.USD","LU1781817850.SGD","LU1064130708.USD","BK0060","LU0359201612.USD","LU1997245177.USD","BK0239","LU1969619763.USD","LU1064131003.USD","LU2328871848.SGD","LU1655091616.SGD","LU1580142542.USD","LU2289578879.USD","LU2488822045.USD","01276","600276","LU1997245094.SGD","LU0359202008.SGD","BK0183","BK1191","LU1146622755.USD","LU2495084118.USD","LU2580892862.HKD","LU2097828714.EUR","BK0196","LU2097828474.EUR","LU2097828805.USD","LU2580892789.USD","LU1820825898.SGD","LU2543165471.USD","LU0405327148.USD","LU0359201885.HKD","LU1328615791.USD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623701399","title":"营收316亿、净利增超21% 恒瑞医药2025年财报释放强劲动能","url":"https://stock-news.laohu8.com/highlight/detail?id=2623701399","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623701399?lang=zh_cn&edition=full","pubTime":"2026-03-30 14:37","pubTimestamp":1774852622,"startTime":"0","endTime":"0","summary":"3月25日，恒瑞医药发布2025年年度报告。报告期内，公司坚持“科技创新+国际化”双轮驱动战略，实现业绩持续增长，营收和净利均再创新高。全年实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%；归属于上市公司股东的扣除非经常性损益的净利润74.13亿元，同比增长20.00%。创新药销售收入163.42亿元，同比增长26.09%，占药品销售收入比重达58.34%；对外许可收入33.92亿元，同比增长25.62%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260330/32111266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623360351","title":"【券商聚焦】交银国际维持恒瑞医药(01276)中性评级 指新品放量+国际化共驱高增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2623360351","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623360351?lang=zh_cn&edition=full","pubTime":"2026-03-30 11:00","pubTimestamp":1774839632,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，恒瑞医药(01276)2025年收入同比增长13%，符合该机构的预期，毛利率与2024年基本持平，研发/SG&A费用率下降1.5/1.3ppt，反映公司运营效率的持续提升。2025 年公司业绩录得较快增速，主要动力来自创新药销售持续放量及对外授权收入的常态化贡献。2026年重点关注新进医保产品放量节奏、ADC及减重领域重点品种III期数据读出、及丰厚早研管线产生的更多BD机会。基于2025年业绩及未来指引，该机构微调公司2026-27 年盈利预测，维持目标价 69.5 港元/63.18 人民币（01276/600276 CH），当前估值合理，维持中性评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622814803","title":"港股异动 | 先声药业(02096)午前涨近8% 恒瑞医药前董事长周云曙正式出任先声药业CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2622814803","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622814803?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:01","pubTimestamp":1774584119,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，先声药业午前涨近8%，截至发稿，涨7.87%，报12.06港元，成交额4559.2万港元。消息面上，3月25日，先声药业公告披露，恒瑞医药原董事长周云曙正式加盟，获聘首席执行官。先声药业近日发布的年度业绩显示。目前，先声药业已拥有10款上市创新药，还有超5款临近上市创新药，预计于2026-2028年获批，蓄力未来持续增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420260.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2289578879.USD","BK1191","LU0405327148.USD","LU1328615791.USD","LU2097828805.USD","LU1655091616.SGD","LU1997245177.USD","LU1820825898.SGD","LU0405327494.USD","LU2488822045.USD","LU2097828474.EUR","BK0183","LU0359202008.SGD","LU0359201612.USD","BK0028","LU1580142542.USD","LU1064130708.USD","BK0060","LU1146622755.USD","LU2580892789.USD","LU2543165471.USD","LU2580892862.HKD","LU2328871848.SGD","LU2097828714.EUR","BK0196","BK0239","LU1781817850.SGD","LU2495084118.USD","LU1023057109.AUD","LU0359201885.HKD","01276","VXUS","LU2097828557.USD","BK0188","02096","LU2148510915.USD","BK4588","BK1583","BK0012","LU1969619763.USD","LU1255011170.USD","LU1997244956.HKD","LU1997245094.SGD","LU2097828631.EUR","LU1064131003.USD","600276","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622289783","title":"信达生物2025年首次扭亏为盈；周云曙出任先声药业CEO | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2622289783","media":"每日经济新闻","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622289783?lang=zh_cn&edition=full","pubTime":"2026-03-27 07:00","pubTimestamp":1774566006,"startTime":"0","endTime":"0","summary":"丨2026年3月27日星期五丨NO.1京东健康宿迁天宁股权结构调整3月26日，京东健康宣布，为提高行政效率，李娅云于2026年3月26日订立股权转让协议，据此李娅云同意将其在宿迁天宁持有的30%股权转让予隋婷婷。由于一名登记股东变更，宿迁天宁、外商独资企业及新登记股东订立新合同安排，现有合同安排同时终止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686096042.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686096042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1580142542.USD","LU2580892789.USD","BK1191","BK1161","LU2495084118.USD","LU1997245177.USD","LU1969619763.USD","BK1515","BK0183","HK0000165453.HKD","LU1997244956.HKD","600276","LU2097828714.EUR","LU0455707207.USD","LU1064131003.USD","02096","LU1820825898.SGD","BK0188","LU2580892862.HKD","LU1328615791.USD","BK1574","LU1781817850.SGD","LU2242644610.SGD","09939","LU0502904849.HKD","159938","LU1997245094.SGD","01801","BK1583","LU1146622755.USD","LU2097828474.EUR","LU1064130708.USD","LU2097828631.EUR","LU2097828805.USD","LU2148510915.USD","LU2289578879.USD","LU2488822045.USD","LU0405327494.USD","LU2097828557.USD","BK0060","BK1589","LU2328871848.SGD","BK0196","LU0405327148.USD","LU1255011170.USD","BK0028","BK0239","BK0012","LU1655091616.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622789788","title":"恒瑞医药创新药收入占比近六成 BD重构国际化价值锚点","url":"https://stock-news.laohu8.com/highlight/detail?id=2622789788","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622789788?lang=zh_cn&edition=full","pubTime":"2026-03-27 07:00","pubTimestamp":1774566000,"startTime":"0","endTime":"0","summary":"3月25日，恒瑞医药（600276.SH，01276.HK）发布2025年年度报告。财报显示，全年实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%；归属于上市公司股东的扣除非经常性损益的净利润74.13亿元，同比增长20.00%。这一增速显著超出行业平均水平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686095212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686095212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","LU1580142542.USD","01276","LU2580892789.USD","BK1191","LU2543165471.USD","BK1161","LU2495084118.USD","LU1997245177.USD","LU1969619763.USD","LU0359201885.HKD","BK0183","LU1997244956.HKD","600276","LU2097828714.EUR","LU1064131003.USD","LU1820825898.SGD","LU2580892862.HKD","BK0188","LU0359201612.USD","LU1328615791.USD","BK1574","LU1781817850.SGD","LU1997245094.SGD","LU1146622755.USD","LU2097828474.EUR","LU2097828805.USD","LU2097828631.EUR","LU0359202008.SGD","LU1064130708.USD","LU1023057109.AUD","LU2148510915.USD","LU2289578879.USD","159992","LU2488822045.USD","LU0405327494.USD","LU2097828557.USD","BK0060","LU2328871848.SGD","BK0196","LU0405327148.USD","LU1255011170.USD","BK0028","BK0239","BK0012","LU1655091616.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622830485","title":"恒瑞医药(600276.SH)：HRS9531注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2622830485","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622830485?lang=zh_cn&edition=full","pubTime":"2026-03-26 16:51","pubTimestamp":1774515073,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS9531注射液的《药物临床试验批准通知书》，将于近期开展临床试验。根据《中华人民共和国药品管理法》及有关规定，经审查，2026年1月7日受理的HRS9531注射液临床试验申请符合药品注册的有关要求，同意本品开展临床试验。申请的适应症：用于降低动脉粥样硬化性心血管疾病患者的主要心血管不良事件风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","BK0012","BK0239","LU2097828714.EUR","LU1580142542.USD","BK0196","01276","BK0183","LU2580892789.USD","LU1997245177.USD","LU0405327148.USD","LU2543165471.USD","LU0359201885.HKD","LU1655091616.SGD","LU2148510915.USD","LU1820825898.SGD","LU2328871848.SGD","BK0028","LU1969619763.USD","BK0060","BK0188","LU1023057109.AUD","LU2097828805.USD","LU1997245094.SGD","LU2495084118.USD","LU1255011170.USD","LU1064130708.USD","LU2097828557.USD","LU0359201612.USD","BK1191","LU0405327494.USD","LU2289578879.USD","600276","LU0359202008.SGD","LU2097828474.EUR","LU1781817850.SGD","LU2580892862.HKD","LU1146622755.USD","LU1997244956.HKD","LU1328615791.USD","LU1064131003.USD","LU2097828631.EUR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1776322321513,"stockEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.0385},{"period":"3month","weight":-0.0861},{"period":"6month","weight":-0.1132},{"period":"1year","weight":0.2003},{"period":"ytd","weight":-0.0309}],"compareEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":-0.0141},{"period":"3month","weight":-0.0208},{"period":"6month","weight":0.0488},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"449644人(较上一季度增加12.84%)","perCapita":"14186股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}